Aza-TdC
Cancer
ClinicalActive
Key Facts
About Nanopharmaceutics
Nanopharmaceutics is a clinical-stage biotech focused on enhancing drug delivery through nanoparticle formulations, primarily for BCS Class II and IV small molecules. The company has a pipeline of nine clinical-stage programs across oncology, CNS, metabolic, and infectious disease indications, supported by a leadership team with a long track record in product development and government contracting. While privately held, it operates as a subsidiary of the public entity TRON Group Inc. (OTC: TGRP) and leverages affiliate Alchem Laboratories for discovery capabilities, positioning itself to address significant unmet needs in targeted drug delivery.
View full company profileOther Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |
| Undisclosed DDR Sensor Program(s) | NERx Biosciences | Pre-clinical |